This decision affirms all but $42 million of a $344 million judgment against Johnson under the UCL and FAL for misleading advertising and concealment of the serious risks entailed in using its pelvic mesh product to cure certain conditions in women.  The trial court applied the proper test in determining whether Johnson’s instructions for use and other advertising would mislead reasonable members of its target audience–doctors.  It also found that Johnson concealed risks known only to it and that its misrepresentations and concealments were material.  That the court denied injunctive relief was not inconsistent with those findings since the case and others like it had brought to public awareness the risks of using the pelvic mesh.  The $42 million in civil penalties was not supported by the evidence, however, since at trial there had been no evidence regarding the oral statements by Johnson drug representatives to doctors for which those penalties had been assessed.